Trastuzumab Deruxtecan (ENHERTU)
HER2-directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload
Trastuzumab Deruxtecan (ENHERTU)
Forms and strengths
Form: TabletStrength: 100 mg/vial (reconstituted to 20 mg/mL)
References
Indication
- Trastuzumab deruxtecan (ENHERTU) is used alone to treat adults with unresectable or metastatic HER2-positive breast cancer who have already received at least one prior anti-HER2 treatment regimen, either for metastatic disease or with recurrence within 6 months of completing earlier treatment.
- It is used alone for HER2-positive breast cancer that has previously been treated with trastuzumab emtansine.
- It is used alone for hormone receptor-positive, HER2-low or HER2-ultralow breast cancer in patients who have had at least one endocrine therapy and are no longer considered candidates for further endocrine treatment.
- It is used alone for HER2-low breast cancer after at least one prior chemotherapy regimen for metastatic disease, or recurrence within 6 months of completing adjuvant chemotherapy.
- It is used alone for unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after a prior trastuzumab-based treatment regimen.
- It is used alone for unresectable or metastatic HER2-positive (IHC 3+) solid tumours in patients who have had prior systemic treatment and have no satisfactory alternative options.
- Treatment requires laboratory confirmation of the tumour's HER2 status using a validated test before starting therapy.
Pregnancy
- Trastuzumab deruxtecan can cause serious harm to a developing fetus and should be avoided during pregnancy.
- There is no human pregnancy data; post-marketing reports with trastuzumab, a related HER2-targeted antibody, describe low amniotic fluid, fatal lung underdevelopment, skeletal problems, and newborn death.
- The topoisomerase I inhibitor component is also expected to cause fetal harm based on its mechanism of action and animal study findings.
- Pregnancy status should be confirmed before starting treatment in patients who could become pregnant.
- Effective contraception is required during treatment and for at least 7 months after the last dose in patients who could become pregnant, and for at least 4 months after the last dose for male patients with partners who could become pregnant.
- Patients should contact their doctor immediately if pregnancy occurs during treatment or within 7 months of the last dose.
Breastfeeding
- It is not known whether trastuzumab deruxtecan passes into human breast milk, though antibodies of this type are known to be present in human milk.
- Breastfeeding should be discontinued before starting treatment, given the potential for serious harm to a nursing infant; it may be resumed about 7 months after the last dose.
Geriatrics
- No overall difference in effectiveness was seen between patients 65 years and older and younger patients.
- Clinical experience suggests some differences in safety with increasing age, including a higher rate of treatment interruptions for adverse reactions.
- No dose adjustment is required based on age alone.
Pediatrics
- Safety and effectiveness in children and adolescents under 18 years of age have not been established, and no pediatric indication is authorized.
Dosage & Administration
- For breast cancer and HER2-positive solid tumours, the recommended dose is 5.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.
- For gastric and gastroesophageal junction cancer, the recommended dose is 6.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.
- Patients should be premedicated with a combination antiemetic regimen before each dose, since nausea and vomiting, including delayed symptoms, are expected.
- The first infusion is given over 90 minutes; later infusions may be shortened to 30 minutes if earlier doses were well tolerated.
- Dose reductions follow a stepwise schedule with two permitted reduction levels; a need for a third reduction means treatment must be stopped.
- Treatment is interrupted or the dose reduced for interstitial lung disease, neutropenia, febrile neutropenia, low platelet counts, or a significant drop in heart pumping function, with permanent discontinuation required for the most severe grades of these events.
- If a planned dose is delayed or missed, it should be given as soon as possible rather than waiting for the next cycle, keeping doses roughly 3 weeks apart.
- No dose adjustment is needed for mild or moderate kidney impairment, though patients with moderate impairment should be watched closely for lung problems; limited data exist for severe kidney impairment.
- No dose adjustment is needed for mild liver impairment; patients with moderate impairment should be monitored closely for increased toxicity, and there is no data for severe liver impairment.
- Trastuzumab deruxtecan must be reconstituted and diluted by a trained health professional and given only as an intravenous infusion through an in-line filter; it must never be given as a rapid injection or bolus.
- Because the name and packaging can be confused with trastuzumab or trastuzumab emtansine, staff should double-check the vial label before preparing or giving each dose.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Information on trastuzumab deruxtecan overdose is limited.
- In clinical studies, doses higher than the recommended dose were associated with a higher rate of severe adverse events.
- There is no antidote for trastuzumab deruxtecan.
- Management involves close patient monitoring and appropriate supportive care.
Common side effects
- Nausea is very common.
- Fatigue is common.
- Vomiting is common.
- Hair loss (alopecia) is common.
- Low red blood cell counts (anemia) are common.
- Low white blood cell counts (neutropenia) are common.
- Constipation is common.
- Decreased appetite is common.
- Diarrhea is common.
- Elevated liver enzymes may occur.
- Musculoskeletal pain may occur.
- Low platelet counts (thrombocytopenia) may occur.
- Low white blood cell counts (leukopenia) may occur.
- Headache may occur.
- Abdominal pain may occur.
- Blurred vision may occur.
- Dizziness may occur.
- Altered sense of taste (dysgeusia) may occur.
- Nosebleeds (epistaxis) may occur.
- Cough may occur.
- Dry eyes may occur.
- Weight loss may occur.
- Mouth sores (stomatitis) may occur.
- Upper respiratory tract infections may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Interstitial lung disease and pneumonitis, including fatal cases, have occurred and require permanent discontinuation once symptomatic.
- A decrease in the heart's pumping ability (left ventricular dysfunction) and heart failure can occur.
- Severe or febrile neutropenia can occur, increasing infection risk.
- Severe thrombocytopenia can occur, increasing bleeding risk.
- Infusion-related reactions, including serious hypersensitivity, have been reported.
- Exposure during pregnancy can seriously harm a developing fetus.
- There is a risk of dangerous medication errors from confusing this drug with trastuzumab or trastuzumab emtansine, which are dosed very differently.
- Seek urgent medical attention for new or worsening cough, shortness of breath, fever, chest pain, an irregular heartbeat, or signs of a severe allergic reaction.
Use with caution
- Use with caution in patients with moderate kidney impairment, who have a higher reported rate of lung-related adverse reactions.
- Use with caution in patients with moderate liver impairment, given the potential for increased drug exposure and toxicity.
- Use with caution in patients with a prior history of interstitial lung disease or pneumonitis.
- Use with caution in patients with pre-existing heart disease or reduced heart pumping function, since this population has not been studied.
- Use with caution in patients of Asian background, who have shown higher rates of low blood cell counts and bleeding events in clinical trials.
- Exercise caution when driving or operating machinery, as fatigue, headache, and dizziness can occur.
- Complete blood counts should be checked before starting treatment and before every dose.
- Heart pumping function should be assessed before starting treatment and at regular intervals during treatment.
Contraindications
- Contraindicated in patients with known hypersensitivity to trastuzumab deruxtecan or to any ingredient in the formulation.
Drug interactions
- Ritonavir, a combined transporter and CYP3A inhibitor, did not meaningfully increase drug exposure, so no dose adjustment is needed when co-administered.
- Itraconazole, a strong CYP3A inhibitor, did not meaningfully increase drug exposure, so no dose adjustment is needed when co-administered.
- No clinically meaningful interaction is expected with inhibitors of the P-glycoprotein, MATE2-K, MRP1, or BCRP drug transporters.
- Trastuzumab deruxtecan's active payload does not inhibit or induce major liver drug-metabolizing enzymes, so it is unlikely to meaningfully change the levels of other drugs.
Food interactions
- Trastuzumab deruxtecan is given only by intravenous infusion in a clinic setting, so food timing does not apply.
- No interactions with food or herbal products have been established.
Time of administration
- Given by intravenous infusion once every 3 weeks by a health professional; timing is not tied to meals or a specific time of day.
- Patients are observed for a period after each infusion to check for reactions.
Storage
- Store vials refrigerated at 2°C to 8°C, protected from light; do not freeze or shake.
- After reconstitution, use immediately, or refrigerate and use within the time limits set by the pharmacy; discard unused vials after the permitted refrigeration window.
- Once diluted for infusion, use promptly, or store briefly at room temperature or refrigerated as directed, protected from light.
Patient take-away
- Trastuzumab deruxtecan (ENHERTU) is a targeted intravenous cancer therapy for several types of HER2-related breast, gastric, and other solid tumours.
- Lung problems (interstitial lung disease) are a serious risk; report any new or worsening cough or shortness of breath right away.
- Heart function is monitored regularly during treatment because of the risk of reduced pumping ability.
- Effective contraception is required during treatment and for months afterward, since this medicine can seriously harm a developing fetus.
- Seek urgent medical attention for breathing problems, chest pain, an irregular heartbeat, or signs of a severe allergic reaction.